Trial of intrathecal rituximab in progressive multiple sclerosis patients with evidence of leptomeningeal contrast enhancement
Pavan Bhargava(Johns Hopkins University), Ellen M. Mowry(Johns Hopkins University), Roy E. Strowd(Wake Forest University), Daniel S. Reich(National Institutes of Health), Cassie Wicken(Johns Hopkins University), Matthew D. Smith(Johns Hopkins University), Peter A. Calabresi(Johns Hopkins University), Irene Cortese(National Institutes of Health)
Cited by 70
Related Papers
Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria
|The Lancet Neurology|2017|8k
A clinical approach to diagnosis of autoimmune encephalitis
|The Lancet Neurology|2016|4.4k
Defining the clinical course of multiple sclerosis
|Neurology|2014|3.1k
MRI criteria for the diagnosis of multiple sclerosis: MAGNIMS consensus guidelines
|The Lancet Neurology|2016|863